Stryker Misses Revenue Estimates at $6.52 Billion; Adjusted EPS Narrowly Short
Stryker updated its 2026 adjusted EPS guidance to $14.80 to $14.90, below the $14.95 average analyst estimate, and its board added $3.0 billion to the buyback program.
Stryker SYK
Stryker Corp · NYSE · Surgical & Medical Instruments & Apparatus
$311.75+2.55%close on Oct. 29, 2026 · volume 3.0M · Yahoo Finance
Price, last 48 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Aug. 21, 2026 | Dylan Bram Crotty Group President · indirect | Sold | 441 | $328.61 | $144,915 |
| Aug. 19, 2026 | Ronda E. Stryker director · indirect | Sold | 50,000 | $340.10 $331.81-$343.47 | $17.01 million |
| Aug. 18, 2026 | Ronda E. Stryker director · indirect | Sold | 300,000 | $335.90 $331.74-$338.50 | $100.77 million |
| Aug. 18, 2026 | Debra King See Remarks | Sold | 826 | $336.30 | $277,787 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 14 →Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedStryker reports Q3 2026 adjusted EPS of $3.52, up 10.3%, below $3.55 consensus, and trims FY2026 adjusted EPS guidance to $14.80-$14.90 versus $14.95 consensus
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedStryker (SYK) announces planned CEO succession: Spencer Stiles to succeed Kevin Lobo as CEO effective January 1, 2027, with Lobo becoming Executive Chair